Clinical Trial Detail

NCT ID NCT03597581
Title A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rgenix, Inc.
Indications

pancreatic adenocarcinoma

small intestine adenocarcinoma

colorectal adenocarcinoma

biliary tract cancer

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

RGX202

Fluorouracil + Irinotecan + Leucovorin + RGX202

Age Groups: adult senior

No variant requirements are available.